GlassScriptPhysician profile
Trushar Patel
NPI 1457511925
$88,299.05
in general payments reported to CMS, 2019-2025
25 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,206 · 2020: $18K · 2021: $6,128 · 2022: $8,840 · 2023: $27K · 2024: $9,454 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Education: $9,940 · Food and Beverage: $6,133 · Honoraria: $3,250 · Travel and Lodging: $3,166 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,790.00 |
| Education | $9,939.99 |
| Food and Beverage | $6,132.97 |
| Honoraria | $3,250.00 |
| Travel and Lodging | $3,165.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $37,760.25 | 2021-2025 | Tisseel, Floseal, Seprafilm |
| Intuitive Surgical, INC. | $37,182.46 | 2019-2023 | Da Vinci Surgical System, Da Vinci Sp |
| Urogen Pharma, INC. | $3,858.51 | 2021-2025 | Jelmyto |
| Histosonics, INC. | $2,423.18 | 2024-2025 | |
| Coloplast Corp | $2,397.82 | 2019-2025 | Titan, Altis, Speedicath |
| Ethicon INC. | $1,250.00 | 2024-2025 | |
| Boston Scientific Corporation | $755.36 | 2019-2025 | Ams 700, Spaceoar Vue System - 10ml, General - Therapies |
| Janssen Biotech, INC. | $720.64 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $341.96 | 2019-2021 | |
| Photocure INC | $271.85 | 2019-2023 | Cysview |
| Endo USA, INC. | $202.56 | 2025 | Xiaflex, Aveed |
| Karl Storz Endoscopy-America | $197.44 | 2019-2023 | Tele Pack |
| Innovation Technologies INC | $169.29 | 2025 | Irrisept |
| Pfizer INC. | $135.29 | 2022 | |
| Neotract INC. | $123.27 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $114.31 | 2024-2025 | |
| Dentsply Sirona INC | $100.00 | 2023 | Primescan Connect |
| Ferring Pharmaceuticals INC. | $94.33 | 2025 | Adstiladrin |
| Becton, Dickinson and Company | $47.54 | 2025 | Bard Urinary Drainage Bag |
| Janssen Scientific Affairs, LLC | $37.92 | 2025 | Erleada |
| Ethicon US, LLC | $27.27 | 2025 | Surgiflo Hemostatic Matrix, Evarrest, Dermabond |
| Angiodynamics, INC. | $25.81 | 2024 | Nanoknife |
| Organogenesis INC. | $24.42 | 2023 | Puraply |
| Procept Biorobotics Corporation | $24.22 | 2024 | Aquabeam System |
| Abbott Laboratories | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trushar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.